SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous sys...
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...
Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...
Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...
A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...
Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...
In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advanc...
In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into t...
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...
Roche (SIX: RO, ROG; OTCQX: RHHBY) that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presente...
© 2025 Biopharma Boardroom. All Rights Reserved.
